
Quarterly report 2025-Q3
added 11-13-2025
AgeX Therapeutics Market Cap 2011-2026 | AGE
As of March 03, 2026 AgeX Therapeutics has a market cap of $ 12.2 K
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap AgeX Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.1 K | 679 | 30.4 M | 65.5 M | 52.6 M | 137 M | - | 132 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 137 M | 679 | 59.7 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
2.77 B | $ 20.22 | -2.32 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
4.09 M | $ 0.82 | -3.48 % | $ 4.47 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Axsome Therapeutics
AXSM
|
8.67 B | $ 164.71 | -1.01 % | $ 8.19 B | ||
|
AbCellera Biologics
ABCL
|
962 M | $ 3.73 | -2.49 % | $ 1.11 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 8.5 | -2.63 % | $ 1.39 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
3.04 B | $ 23.88 | - | $ 2.92 B | ||
|
Corvus Pharmaceuticals
CRVS
|
94.1 M | $ 18.08 | 1.06 % | $ 868 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Certara
CERT
|
1.08 B | $ 7.19 | 1.93 % | $ 1.15 B | ||
|
Eton Pharmaceuticals
ETON
|
114 M | $ 17.72 | -2.37 % | $ 454 M | ||
|
Exelixis
EXEL
|
11.7 B | $ 40.99 | -0.1 % | $ 11.1 B | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Galapagos NV
GLPG
|
4.42 B | $ 33.13 | -2.82 % | $ 2.69 B | ||
|
Greenwich LifeSciences
GLSI
|
115 M | $ 27.7 | 1.12 % | $ 361 M | ||
|
Genmab A/S
GMAB
|
25 B | $ 27.67 | -6.69 % | $ 17.7 B | ||
|
Capricor Therapeutics
CAPR
|
155 M | $ 26.04 | -3.07 % | $ 697 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
Codexis
CDXS
|
291 M | $ 0.99 | -2.92 % | $ 72.7 M | ||
|
Halozyme Therapeutics
HALO
|
9.66 B | $ 69.39 | -0.67 % | $ 8.32 B | ||
|
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 28.56 | -1.19 % | $ 1.64 B | ||
|
ImmuCell Corporation
ICCC
|
40.9 M | $ 6.3 | -3.67 % | $ 51.5 M | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Immuron Limited
IMRN
|
348 M | $ 0.75 | -0.69 % | $ 6.43 M | ||
|
Immatics N.V.
IMTX
|
503 M | $ 9.86 | -1.3 % | $ 620 M | ||
|
Immunic
IMUX
|
145 M | $ 1.1 | 3.3 % | $ 171 M | ||
|
Immunovant
IMVT
|
2.26 B | $ 26.99 | -2.74 % | $ 4.09 B | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Inhibrx
INBX
|
1.75 B | $ 75.96 | -1.97 % | $ 3.58 B | ||
|
InMed Pharmaceuticals
INM
|
1.71 M | $ 0.75 | -8.49 % | $ 1.84 M | ||
|
INmune Bio
INMB
|
211 M | $ 1.41 | 6.07 % | $ 25.4 M | ||
|
Insmed Incorporated
INSM
|
31.6 B | $ 146.89 | 0.39 % | $ 29.2 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
215 K | $ 3.19 | -4.49 % | $ 1.14 M | ||
|
Innate Pharma S.A.
IPHA
|
363 M | $ 1.63 | -1.21 % | $ 235 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 29.11 | -0.31 % | $ 1.69 B |